Literature DB >> 18589009

Heparanase expression and activity influences chondrogenic and osteogenic processes during endochondral bone formation.

A J Brown1, M Alicknavitch, S S D'Souza, T Daikoku, C B Kirn-Safran, D Marchetti, D D Carson, M C Farach-Carson.   

Abstract

Endochondral bone formation is a highly orchestrated process involving coordination among cell-cell, cell-matrix and growth factor signaling that eventually results in the production of mineralized bone from a cartilage template. Chondrogenic and osteogenic differentiation occur in sequence during this process, and the temporospatial patterning clearly requires the activities of heparin binding growth factors and their receptors. Heparanase (HPSE) plays a role in osteogenesis, but the mechanism by which it does so is incompletely understood. We used a combination of ex vivo and in vitro approaches and a well described HPSE inhibitor, PI-88 to study HPSE in endochondral bone formation. In situ hybridization and immunolocalization with HPSE antibodies revealed that HPSE is expressed in the peri-chondrium, peri-osteum, and at the chondro-osseous junction, all sites of key signaling events and tissue morphogenesis. Transcripts encoding Hpse also were observed in the pre-hypertrophic zone. Addition of PI-88 to metatarsals in organ culture reduced growth and suggested that HPSE activity aids the transition from chondrogenic to osteogenic processes in growth of long bones. To study this, we used high density cultures of ATDC5 pre-chondrogenic cells grown under conditions favoring chondrogenesis or osteogenesis. Under chondrogenic conditions, HPSE/Hpse was expressed at high levels during the mid-culture period, at the onset of terminal chondrogenesis. PI-88 addition reduced chondrogenesis and accelerated osteogenesis, including a dramatic up-regulation of osteocalcin levels. In normal growth medium, addition of PI-88 reduced migration of ATDC-5 cells, suggesting that HPSE facilitates cartilage replacement by bone at the chondro-osseous junction by removing the HS component of proteoglycans, such as perlecan/HSPG2, that otherwise prevent osteogenic cells from remodeling hypertrophic cartilage.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18589009      PMCID: PMC2621444          DOI: 10.1016/j.bone.2008.05.022

Source DB:  PubMed          Journal:  Bone        ISSN: 1873-2763            Impact factor:   4.398


  85 in total

1.  Human mononuclear cells contain an endoglycosidase specific for heparan sulphate glycosaminoglycan demonstrable with the use of a specific solid-phase metabolically radiolabelled substrate.

Authors:  R F Sewell; P E Brenchley; N P Mallick
Journal:  Biochem J       Date:  1989-12-15       Impact factor: 3.857

2.  Syndecan-3, tenascin-C, and the development of cartilaginous skeletal elements and joints in chick limbs.

Authors:  E Koyama; J L Leatherman; A Shimazu; H D Nah; M Pacifici
Journal:  Dev Dyn       Date:  1995-06       Impact factor: 3.780

3.  Induction of bone-related proteins, osteocalcin and osteopontin, and their matrix ultrastructural localization with development of chondrocyte hypertrophy in vitro.

Authors:  J B Lian; M D McKee; A M Todd; L C Gerstenfeld
Journal:  J Cell Biochem       Date:  1993-06       Impact factor: 4.429

4.  Production of heparanase by normal and neoplastic murine B-lymphocytes.

Authors:  R Laskov; R I Michaeli; H Sharir; E Yefenof; I Vlodavsky
Journal:  Int J Cancer       Date:  1991-01-02       Impact factor: 7.396

5.  Heparin structure and interactions with basic fibroblast growth factor.

Authors:  S Faham; R E Hileman; J R Fromm; R J Linhardt; D C Rees
Journal:  Science       Date:  1996-02-23       Impact factor: 47.728

6.  Sequence variation in heparin octasaccharides with high affinity for antithrombin III.

Authors:  D H Atha; A W Stephens; A Rimon; R D Rosenberg
Journal:  Biochemistry       Date:  1984-11-20       Impact factor: 3.162

7.  Degradation of heparan sulfate in the subendothelial extracellular matrix by a readily released heparanase from human neutrophils. Possible role in invasion through basement membranes.

Authors:  Y Matzner; M Bar-Ner; J Yahalom; R Ishai-Michaeli; Z Fuks; I Vlodavsky
Journal:  J Clin Invest       Date:  1985-10       Impact factor: 14.808

8.  Extension and structural variability of the antithrombin-binding sequence in heparin.

Authors:  U Lindahl; L Thunberg; G Bäckström; J Riesenfeld; K Nordling; I Björk
Journal:  J Biol Chem       Date:  1984-10-25       Impact factor: 5.157

9.  Characterization of heparan sulfate oligosaccharides that bind to hepatocyte growth factor.

Authors:  S Ashikari; H Habuchi; K Kimata
Journal:  J Biol Chem       Date:  1995-12-08       Impact factor: 5.157

10.  Heparin-binding EGF-like growth factor gene is induced in the mouse uterus temporally by the blastocyst solely at the site of its apposition: a possible ligand for interaction with blastocyst EGF-receptor in implantation.

Authors:  S K Das; X N Wang; B C Paria; D Damm; J A Abraham; M Klagsbrun; G K Andrews; S K Dey
Journal:  Development       Date:  1994-05       Impact factor: 6.868

View more
  21 in total

1.  Heparan sulfate-dependent signaling of fibroblast growth factor 18 by chondrocyte-derived perlecan.

Authors:  Christine Y Chuang; Megan S Lord; James Melrose; Martin D Rees; Sarah M Knox; Craig Freeman; Renato V Iozzo; John M Whitelock
Journal:  Biochemistry       Date:  2010-07-06       Impact factor: 3.162

2.  Stage-specific control of connective tissue growth factor (CTGF/CCN2) expression in chondrocytes by Sox9 and beta-catenin.

Authors:  Bau-Lin Huang; Sean M Brugger; Karen M Lyons
Journal:  J Biol Chem       Date:  2010-06-22       Impact factor: 5.157

Review 3.  Border patrol: insights into the unique role of perlecan/heparan sulfate proteoglycan 2 at cell and tissue borders.

Authors:  Mary C Farach-Carson; Curtis R Warren; Daniel A Harrington; Daniel D Carson
Journal:  Matrix Biol       Date:  2013-08-31       Impact factor: 11.583

4.  Deficiency in perlecan/HSPG2 during bone development enhances osteogenesis and decreases quality of adult bone in mice.

Authors:  Dylan A Lowe; Nadia Lepori-Bui; Peter V Fomin; Laura G Sloofman; Xiaozhou Zhou; Mary C Farach-Carson; Liyun Wang; Catherine B Kirn-Safran
Journal:  Calcif Tissue Int       Date:  2014-05-06       Impact factor: 4.333

5.  Heparanase stimulates chondrogenesis and is up-regulated in human ectopic cartilage: a mechanism possibly involved in hereditary multiple exostoses.

Authors:  Julianne Huegel; Motomi Enomoto-Iwamoto; Federica Sgariglia; Eiki Koyama; Maurizio Pacifici
Journal:  Am J Pathol       Date:  2015-04-08       Impact factor: 4.307

Review 6.  Heparan sulfate in skeletal development, growth, and pathology: the case of hereditary multiple exostoses.

Authors:  Julianne Huegel; Federica Sgariglia; Motomi Enomoto-Iwamoto; Eiki Koyama; John P Dormans; Maurizio Pacifici
Journal:  Dev Dyn       Date:  2013-07-29       Impact factor: 3.780

7.  Single molecule force measurements of perlecan/HSPG2: A key component of the osteocyte pericellular matrix.

Authors:  Sithara S Wijeratne; Jerahme R Martinez; Brian J Grindel; Eric W Frey; Jingqiang Li; Liyun Wang; Mary C Farach-Carson; Ching-Hwa Kiang
Journal:  Matrix Biol       Date:  2015-11-04       Impact factor: 11.583

8.  Transcriptional activation by NFκB increases perlecan/HSPG2 expression in the desmoplastic prostate tumor microenvironment.

Authors:  Curtis R Warren; Brian J Grindel; Lewis Francis; Daniel D Carson; Mary C Farach-Carson
Journal:  J Cell Biochem       Date:  2014-07       Impact factor: 4.429

9.  Matrilysin/matrix metalloproteinase-7(MMP7) cleavage of perlecan/HSPG2 creates a molecular switch to alter prostate cancer cell behavior.

Authors:  B J Grindel; J R Martinez; C L Pennington; M Muldoon; J Stave; L W Chung; M C Farach-Carson
Journal:  Matrix Biol       Date:  2014-05-14       Impact factor: 11.583

10.  Perlecan/HSPG2: Signaling role of domain IV in chondrocyte clustering with implications for Schwartz-Jampel Syndrome.

Authors:  Jerahme R Martinez; Brian J Grindel; Kelsea M Hubka; George R Dodge; Mary C Farach-Carson
Journal:  J Cell Biochem       Date:  2018-09-11       Impact factor: 4.429

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.